Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Current cost-effectiveness analyses (CEA) emphasize drug costs as the differentiator between NICE recommended anti-VEGF treatments but may neglect real-world non-drug costs of running nAMD services in the UK. To address this, this study identified real-world non-drug service cost items relevant to UK NHS nAMD clinics, including costs arising from operational strain (demand exceeding capacity). METHODS: Cost items were identified by a structured literature review of peer-reviewed and grey literature, and an expert panel of 10 UK-based ophthalmologists with relevance to real-world practice. These items underwent meta-synthesis and were then determined in a consensus exercise. RESULTS: Of 237 cost items identified, 217 (91.6%) met the consensus threshold of >0.51 and were included in the nAMD Service Non-Drug Cost Instrument (nAS). Sensitivity of cost items taken from UK Health Technology Assessment (HTA) using the nAS as the reference standard was low (HTAmin: 1.84%, 95% CI 0.50-4.65%; HTAmax: 70.51%, 95% CI 63.96-76.49%). False negative rates showed variable likelihood of misclassifying a service by cost burden depending on prevalence. Scenario analysis using cost magnitudes estimated annual per-patient clinic cost at £845 (within capacity) to £13,960 (under strain) compared to an HTAmin estimate of £210. Accounting for cost of strain under an assumed 50% increase in health resource utilization influenced cost-effectiveness in a hypothetical genericisation scenario. CONCLUSION: Findings suggested that HTA underestimates UK NHS nAMD clinic cost burden with cost of strain contributing substantial additional unmeasured expense with impact on CEA. Given potential undertreatment due to strain, durability is suggested as one of the relevant factors in CEA of nAMD anti-VEGF treatments due to robustness under limited capacity conditions affecting UK ophthalmology services.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research has suggested that the delivery of anti-VEGF injections is a major cost-driver and is expected to increase over time [12, 50, 67, 68].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [67]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While the high price of anti-VEGFs contributes to increasing costs, their long-term associated care – requiring careful follow-up and monitoring from skilled practitioners - is also a financial strain on patients and health systems that is not fully captured by current costing studies [12, 13, 67].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092 · cited 1×
“Initial title and abstract screening were conducted by two research analysts using Rayyan, a web-based tool designed to facilitate the systematic review process by streamlining the management and screening of citations 43 .”
MethodCochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Guidance for conducting systematic scoping reviews
Peters, M. D. J., Godfrey, C. M., Khalil, H., McInerney, P., Parker, D., & Soares, C. B. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000050 · Cited by 7,472 · cited 1×
“…lent itself to ongoing refinement of the protocol and criteria based on principles of the Joanna Briggs Institute framework for systematic scoping reviews although some modifications were made to account for the specific, targeted nature of the search relating to cost concept identification 42 .”
MethodRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.014 · Cited by 823 · cited 1×
“Our findings suggest that existing approaches of accounting for parameter uncertainty in HEA using statistical meth-ods are insufficient and that definition and accounting of all relevant costs of service delivery are needed 15,69 .”
MethodHeier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785 · cited 1×
“…ANCHOR, MARINA, VIEW I & II, HAWK, HARRIER, TENAYA and LUCERNE, NICE recognizes no clinically significant differences in safety and efficacy between anti-VEGF treatments in nAMD but states that cost-effectiveness may be influenced by net acquisition, administration and monitoring costs 12,17–21 .”
BackgroundSelf-citationHow does burnout affect physician productivity? A systematic literature review
Dewa, C. S., Loong, D., Bonato, S., Thanh, N. X., & Jacobs, P. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-325 · Cited by 622
Research works printed but not linked: 1
- British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Updated September 2018. Available from: https://vnras.com/wp-content/uploads/pdf/BNF-76.pdf.
Cited by
Butler, E. T. S., Arnold‐Vangsted, A., Schou, M. G., Anguita, R., Bjerager, J., Borrelli, E., Cehofski, L. J., Desideri, L. F., van Dijk, E. H. C., Faber, C., et al. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17506 · Cited by 23
“…net surplus for treating neovascular AMD with intravitreal anti-VEGF injections, but the size of the surplus depends on the details of the organization (Abdalla et al., 2024; Neubauer et al., 2010; Quist et al., 2025; Ruiz-Moreno et al., 2021; Sivaprasad et al., 2024; Y ı ld ı r ı m et al., 2018).”
Wojciechowski, P., Wdowiak, M., Panek, M., Lunk, I., Carrasco, J., Zhang, X., Wu, O., Korobelnik, J.-F., & Lanzetta, P. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01098-y · Cited by 21
Cochrane corner: artificial intelligence for diagnosing exudative age-related macular degeneration
Ong, A. Y., Hogg, H. D. J., & Keane, P. A. (2025) · Eye · doi:10.1038/s41433-025-03599-3 · Cited by 6
“…on healthcare resources due to the need for ongoing monitoring and treatment with costly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections [4], with late diagnosis and delayed treatment initiation producing diminishing returns in terms of long-term visual outcomes [5].”
Hogg, H. D. J., Talks, J. S., Engelmann, J., Teare, M. D., Pogose, M., Patel, P. J., Balaskas, K., Maniatopoulos, G., & Keane, P. A. (2025) · Eye · doi:10.1038/s41433-025-04025-4 · Cited by 3
“The economic impact of this capacity-demand mismatch will be non-linear as the annual non-drug cost per nAMD patient of service delivery has been estimated at £845, compared to £13,960 when a service’s capacity is exceeded [10].”
Self-citationGale, R. P., Awad, M. H., Bailey, C., Cackett, P., Chhabra, R., Downey, L., Ghanchi, F. D., Kotagiri, A. K., Narendran, N., Pearce, I., et al. (2026) · Eye · doi:10.1038/s41433-025-04180-8 · Cited by 3
“Long-acting and durable therapies, such as aflibercept 8 mg, offer a potential solution to alleviate some of this strain [7, 41] and, by enabling clinics to operate within capacity, can improve patient outcomes through timely treatment while reducing clinic costs [5, 42].”
Self-citation
Metadata
- Authors
- Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., Pearce, I., Rennie, C., Talks, J., Wojcik, R., & Jandhyala, R.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University Hospitals Bristol and Weston NHS Foundation Trust (GB)
- Hull University Teaching Hospitals NHS Trust (GB)
- Department of Ophthalmology, Bayer PLC, Reading, UK
- York Teaching Hospital NHS Foundation Trust (GB)
- Sunderland Eye Infirmary (GB)
- University of Manchester (GB)
- Aston University (GB)
- Royal Liverpool and Broadgreen University Hospital NHS Trust (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Senior Leadership Team, Medialis Ltd, UK
- Corresponding author
- Jandhyala, Ravi
- ORCID
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2024-06-12
- Volume
- 40
- Issue
- 7
- Pages
- 1221-1233
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W4399170971
- Cited by
- 15
- References
- 70
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 1
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, anti-VEGF therapy, health resource utilization, cost-effectiveness, health technology assessment, undertreatment
- MeSH terms
- Cost-Benefit Analysis, United Kingdom, Humans, Health Care Costs, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. https://app.cochat.ai/papers/10.1080/03007995.2024.2362278
- The paper
- Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., Pearce, I., Rennie, C., Talks, J., Wojcik, R., & Jandhyala, R. (2024). Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2024.2362278
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.